Alligator Bioscience publishes prospectus in connection with forthcoming rights issue
STOCKHOLM, Dec. 30, 2020 /PRNewswire/ T
he Board of Directors of Alligator Bioscience AB (publ) ( Alligator or the Company ) has, in connection with the rights issue of shares which was resolved upon by the Board of Directors on December 15, 2020 pursuant to the authorization from the Annual General Meeting on May 5, 2020 (the Rights Issue ), prepared a prospectus (the Prospectus ) that today has been approved and registered by the Swedish Financial Supervisory Authority.
To ensure continued successful development in accordance with the Company s business plan and strategy, the Board of Directors of Alligator has resolved to carry out the Rights Issue of approximately SEK 86 million before issue costs. The expected net proceeds from the Rights Issue will be used to initiate and conduct Phase II studies for mitazalimab and to complete phase I study and initiate preparatory work on Phase II s
Alligator Bioscience recruits new Chief Medical Officer
LUND, Sweden, Dec. 29, 2020 /PRNewswire/
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that the company has appointed Dr Christina Reimer as Chief Medical Officer. She most recently comes from a position as Senior Medical Director at Ferring Pharmaceuticals in Copenhagen.
Dr Reimer will replace Dr Charlotte Russel and be overall medically responsible for Alligator s drug development candidates, with an emphasis on bringing mitazalimab and ATOR-1017 into Phase II efficacy studies. She will report to Head of R&D, EVP Malin Carlsson, and be part of the management team. I am very pleased with the successful recruitment of Christina Reimer to Alligator. Her international experience in leading clinical development and in building development organizations will significantly strengthen our clinical capacity. This is crucial in the phase we are in now, with two products on the way to Phase II and another produc
Share this article
LUND, Sweden, Dec. 28, 2020 /PRNewswire/
Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced that it has submitted a CTA (Clinical Trial Authorization) application to the relevant regulatory authorities to start a Phase II efficacy study of its wholly-owned CD40 targeting antibody mitazalimab.
The upcoming Phase II study OPTIMIZE-1 is an open-label, multi-center study assessing the clinical efficacy of mitazalimab in combination with chemotherapy (mFolfirinox) in patients with metastatic pancreatic cancer. The OPTIMIZE-1 study will be performed at several clinics in Europe and encompass up to a total of 66 patients. Inclusion of the first patient is planned during the first half of 2021 and will begin with a run-in period to determine the best dose for the combination with chemotherapy.
INVITATION: INVISIO invites you to a conference call December 22 at 10:00 CET
STOCKHOLM, Dec. 22, 2020 /PRNewswire/
INVISIO is pleased to invite press, investors and analysts to a conference call on December 22 at 10.00 CET where CEO Lars Højgård Hansen will present the acquisition of Racal Acoustics.
The conference call, which will be held in English, will begin with a presentation of the acquisition followed by a Q&A session.
Phone number for the conference:
To participate in the conference call, use the dial-in numbers below. Please dial in 5-10 minutes prior to the scheduled start time in order to facilitate a timely start.
PRN: INVISIO acquires Racal Acoustics, a world-leading UK-based supplier of communication and hearing protection solutions comunicati.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from comunicati.net Daily Mail and Mail on Sunday newspapers.